Access the full text.
Sign up today, get DeepDyve free for 14 days.
Z. Xu-Monette, M. Tu, K. Jabbar, Xin Cao, A. Tzankov, C. Visco, Q. Cai, S. Montes-Moreno, Yuji An, K. Dybkaer, A. Chiu, A. Orazi, Y. Zu, G. Bhagat, K. Richards, E. Hsi, W. Choi, J. Krieken, J. Huh, M. Ponzoni, A. Ferreri, Xiaoying Zhao, M. Møller, J. Farnen, J. Winter, M. Piris, R. Miranda, L. Medeiros, K. Young (2015)
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countriesOncotarget, 6
M. Maurer, H. Ghesquières, J. Jais, T. Witzig, C. Haioun, C. Thompson, R. Delarue, I. Micallef, F. Peyrade, W. Macon, Thierry Molina, N. Ketterer, S. Syrbu, O. Fitoussi, Paul Kurtin, C. Allmer, E. Nicolas‐Virelizier, S. Slager, T. Habermann, B. Link, G. Salles, H. Tilly, J. Cerhan (2014)
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 10
L. Sehn, M. Hertzberg, Stephen Opat, A. Herrera, S. Assouline, C. Flowers, T. Kim, A. McMillan, M. Özcan, V. Safar, G. Salles, G. Ku, J. Hirata, Y. Chang, L. Musick, M. Matasar (2021)
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort dataBlood Advances, 6
M. Beylot‐Barry, D. Mermin, A. Maillard, R. Bouabdallah, N. Bonnet, A. Duval-Modeste, L. Mortier, S. Ingen-Housz-Oro, C. Ram-Wolff, S. Barete, S. Dalle, E. Maubec, G. Quéreux, I. Templier, M. Bagot, F. Grange, P. Joly, B. Vergier, P. Vially, A. Gros, A. Pham‐Ledard, E. Frison, J. Merlio (2018)
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.The Journal of investigative dermatology, 138 9
A. Pang, R. Au-Yeung, R. Leung, Y. Kwong (2019)
Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinibAnnals of Hematology
C. Raimondo, F. Abdulla, J. Zain, C. Querfeld, S. Rosen (2019)
Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B‐cell lymphoma, leg typeBritish Journal of Haematology, 187
Nancy Senff, E. Noordijk, Youn Kim, M. Bagot, E. Berti, L. Cerroni, R. Dummer, M. Duvic, R. Hoppe, N. Pimpinelli, S. Rosen, M. Vermeer, S. Whittaker, R. Willemze (2008)
European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.Blood, 112 5
Annals of Hematology (2022) 101:2353–2354 https://doi.org/10.1007/s00277-022-04899-4 LE T TER TO THE EDITOR Eec ff tive treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B‑cell lymphoma leg type 1 2 1 Satoko Oka · Kazuo Ono · Masaharu Nohgawa Received: 9 May 2022 / Accepted: 13 June 2022 / Published online: 9 August 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 2 2 Dear Editor, (300 mg/m , day -6), etoposide (200 mg/m , days -5 to Primary cutaneous diffuse large B-cell lymphoma, leg -2), cytarabine (200 mg/m , days -5 to -2), and melphalan type (PCDLBCL-LT) is a rare and aggressive lymphoma. (140 mg/m , day -1), followed by the infusion of CD34 at The European Organization Society for Cutaneous Lympho- 1.8 × 10 /kg. The CR of lymphoma was confirmed in PET/ mas consensus recommendations indicate immunochemo- CT scans. One month later, relapse was detected at the therapy with R-CHOP as a first-line treatment [1 ]. Although original sites. With informed consent, ibrutinib (140 mg/ previous studies reported the significant clinical activity day) was initiated and the dose was increased up to 560 mg/ of lenalidomide or ibrutinib for PCDLBCL-LT, there are day. Marked improvements
Annals of Hematology – Springer Journals
Published: Oct 1, 2022
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.